Sarepta Therapeutics Inc
NASDAQ:SRPT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Sarepta Therapeutics Inc
Relative Value
The Relative Value of one
SRPT
stock under the Base Case scenario is
265.51
USD.
Compared to the current market price of 122.84 USD,
Sarepta Therapeutics Inc
is
Undervalued by 54%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
SRPT Competitors Multiples
Sarepta Therapeutics Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
11.6B USD | 8.3 | 683.8 | -214.4 | -119.8 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
297.7B USD | 5.5 | 50 | 14 | 21.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
160.2B USD | 5.4 | 42.6 | 18.1 | 29.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.2B USD | 12.2 | 30.9 | 26.1 | 27.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
114.2B USD | 8.7 | 29.6 | 24 | 26.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
139.1B AUD | 6.5 | 37.2 | 22.4 | 27.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.1B USD | 3 | 167.5 | 8.5 | 11.2 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
53.6B USD | 10.4 | -9 | -10 | -8.9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33.7B USD | 3.5 | 28.9 | 14.7 | 18.4 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38T KRW | 16.4 | 96.7 | 48.7 | 81.3 |
You don't have any saved screeners yet
